


JC17 Rec'd PCT/PTO 20 SEP 2005

AMENDMENTS TO THE CLAIMS

Claims 1-66 (cancelled)

67. (new) A double-stranded compound comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein said compound comprises at least one locked nucleic acid (LNA) monomer having the structure



wherein

X is selected from the group consisting of O, S and NRⁿ, where Rⁿ is H or C₁₋₄-alkyl;

Y is CH₂;

B is a nucleobase;

Z and Z* are independently absent or selected from the group consisting of an internucleoside linkage group, a terminal group and a protection group; so that when the LNA monomer is located at the 3' end, Z is a terminal group and Z* is an internucleoside linkage group; when the LNA monomer is located at the 5' end, Z is absent and Z* is a terminal group; and when the LNA monomer is located within the nucleotide sequence, Z is absent and Z* is an internucleoside linkage group.

68. (new) The compound according to claim 67, wherein the sense strand comprises at least one LNA monomer.

69. (new) The compound according to claim 68, wherein the sense strand comprises 1-10 LNA monomers.
70. (new) The compound according to claim 68, wherein at least one LNA monomer is located at the 5' end of the sense strand.
71. (new) The compound according to claim 70, wherein at least two LNA monomers are located at the 5' end of the sense strand.
72. (new) The compound according to claim 67, wherein at least one LNA monomer is located at the 3' end of the sense strand.
73. (new) The compound according to claim 72, wherein at least two LNA monomers are located at the 3' end of the sense strand.
74. (new) The compound according to claim 67, wherein the antisense strand comprises at least one LNA monomer.
75. (new) The compound according to claim 74, wherein the antisense strand comprises 1-10 LNA monomers.
76. (new) The compound according to claim 74, wherein at least one LNA monomer is located at the 3' end of the antisense strand.
77. (new) The compound according to claim 76, wherein at least two LNA monomers are located at the 3' end of the antisense strand.
78. (new) The compound according to claim 77, wherein at least three LNA monomers are located at the 3' end of the antisense strand.
79. (new) The compound according to claim 67, wherein no LNA monomer is located at the 5' end of the antisense strand.
80. (new) The compound according to claim 67, wherein the sense strand comprises at least one LNA and the antisense strand comprises at least one LNA monomer.
81. (new) The compound according to claim 80, wherein the sense strand comprises 1-10 LNA monomers and the antisense strand comprises 1-10 LNA monomers.

82. (new) The compound according to claim 80, wherein the sense strand comprises at least one LNA monomer at the 5' end and at least one LNA monomer at the 3' end, and wherein the antisense strand comprises at least one LNA monomer at the 3' end.

83. (new) The compound according to claim 82, wherein the sense strand comprises at least one LNA monomer at the 5' end and at least one LNA monomer at the 3' end, and wherein the antisense strand comprises at least two LNA monomers at the 3' end.

84. (new) The compound according to claim 83, wherein the sense strand comprises at least two LNA monomers at the 5' end and at least two LNA monomers at the 3' end, and wherein the antisense strand comprises at least two LNA monomers at the 3' end.

85. (new) The compound according to claim 84, wherein the sense strand comprises at least two LNA monomers at the 5' end and at least two LNA monomers at the 3' end, and wherein the antisense strand comprises at least three LNA monomers at the 3' end.

86. (new) The compound according to claim 80, wherein no LNA monomer is located at the 5' end of the antisense strand.

87. (new) The compound according to claim 67, wherein the sense strand comprises at least one LNA monomer in at least one of the positions 9-13 counted from the 5' end.

88. (new) The compound according to claim 87, wherein the sense strand comprises a LNA monomer in position 10.

89. (new) The compound according to claim 87, wherein the sense strand comprises a LNA monomer in position 11.

90. (new) The compound according to claim 87, wherein the sense strand comprises a LNA monomer in position 12.

91. (new) The compound according to claim 67, wherein each strand comprises 17-25 nucleotides.

92. (new) The compound according to claim 91, wherein each strand comprises 20-22 nucleotides.

93. (new) The compound according to claim 67, wherein at least one of the strands has a 3' overhang.

94. (new) The compound according to claim 67, wherein X is selected from the group consisting of O, S and NH.

95. (new) The compound according to claim 94, wherein X is O.

96. (new) The compound according to claim 67, wherein said LNA monomer is in the beta-D form.

97. (new) A pharmaceutical composition comprising the compound according to claim 67 and a pharmaceutically acceptable diluent, carrier or adjuvant.

98. (new) A method for treating cancer, said method comprising administering a compound as defined in claim 67 to a patient in need thereof.

99. (new) A method for treating cancer, said method comprising administering a compound as defined in claim 67 to a patient in need thereof and further comprising the administration of a further chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacilli calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen) daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab) hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin);

interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

100. (new) A method for treating Severe Acute Respiratory Syndrome (SARS), said method comprising administering a compound as defined in claim 67 to a patient in need thereof.

101. (new) A method for treating arteriosclerosis, psoriasis, diabetic retinopathy, rheumatic arthritis, asthma, warts or allergic dermatitis, said method comprising administering a compound as defined in claim 67 to a patient in need thereof.